AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04177017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no.
Study NCT03684265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Capsule (Test)
Description: single dose
Study NCT03513965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptoms as Positive Signals Mindset
Description: In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
Study NCT03513965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptoms as Side Effects Mindset
Description: In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
Study NCT04108585 — intervention group
Intervention type: PROCEDURE
Intervention: HFO therapy
Description: HFO therapy from mechanical ventilation
Study NCT04108585 — intervention group
Intervention type: PROCEDURE
Intervention: CPAP therapy
Description: CPAP therapy from mechanical ventilation
Study NCT01980706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen is a GABA-B agonist
Study NCT01980706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill containing no pharmacologically active substance.
Study NCT02237157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, local delivery
Description: Intra-arterial targeted drug delivery
Study NCT04419246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia will be applied in accordance with standard procedures
Study NCT04419246 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia will be applied in accordance with standard procedures
Study NCT04507763 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Patients with ankylosing spondylitis as provided in real world practice
Study NCT00501215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroid Surgery
Description: Parathyroid surgery 1-3 weeks after the first PSG.
Study NCT00501215 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Interview
Description: Interview about sleep quality lasting 15-20 minutes.
Study NCT04120870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate Injection 0.2 mg/kg
Description: The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
Study NCT02177006 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sun Protection Program
Description: The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys
Study NCT02903238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
Study NCT02903238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Lactose capsule
Study NCT04120870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine injection 2 mg/kg
Description: The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
Study NCT03243084 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
Study NCT00501215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Interview
Description: Interview about sleep quality lasting 15-20 minutes.
Study NCT00501215 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parathyroid Surgery
Description: Parathyroid surgery after completing the second PSG and after the study participation ends.
Study NCT01863056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-Stand Desk
Description: Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
Study NCT00857259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5 mg oral tablet
Study NCT00857259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 5 mg oral tablet
Study NCT00857259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg administered by intravitreal injection
Study NCT04838028 — intervention group
Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia
Study NCT00501215 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Polysomnography (PSG)
Description: 2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview
Study NCT03684265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablet (Reference)
Description: single dose
Study NCT03630224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte Viaflo
Description: Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
Study NCT03630224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
Study NCT04838028 — intervention group
Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia
Study NCT03037034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forcep
Description: Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current.
Study NCT00317642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine (IV formulation)
Description: clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
Study NCT00317642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo (sodium Chloride) 1-hour IV infusion
Study NCT00317642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
Study NCT00501215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Description: 2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview
Study NCT01962714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-Kindness Meditation
Description: 12-week loving-kindness meditation course
Study NCT01962714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: 12-week CPT course
Study NCT00895518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) Therapy
Description: Three PE sessions lasting 1 hour each, delivered 1 week apart
Study NCT00680186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: PRN (to maintain a target INR of 2.0-3.0)
Study NCT00680186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150mg bid
Study NCT00094458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab infusion; AZA placebo caps
Description: Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
Study NCT02526719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple Delay surgery
Description: The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
Study NCT00094458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infliximab (IFX) infusion; azathioprine (AZA) caps
Description: AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
Study NCT00094458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Description: AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
Study NCT03393416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
Study NCT03393416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study.
Study NCT02467647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02467647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Study NCT02467647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLJDT
Study NCT03416738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantically focused treatment
Description: Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation.
Study NCT03416738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phonologically focused treatment
Description: Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation.
Study NCT03243084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
Study NCT03183310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
Study NCT03183310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
Study NCT03183310 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
Study NCT03183310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
Study NCT00744614 — intervention group
Intervention type: PROCEDURE
Intervention: Capnography
Description: A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
Study NCT02104934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Study NCT02066337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Study NCT02066337 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Study NCT02066337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Study NCT02066337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozonated olive oil gel
Study NCT01642524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hypertonic saline mixed Dextran
Description: single dose administered intravenously
Study NCT01642524 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: placebo - saline solution
Study NCT01747278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
Study NCT03966105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HE and Congo red staining
Description: Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
Study NCT02456870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Overfeeding
Description: Consumption of 40% excess calories for 7 consecutive days
Study NCT02852148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTICOAT
Description: ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
Study NCT01892098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: 9mg elemental zinc via 23mg zinc sulfate/day
Study NCT01892098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose pill given as placebo
Study NCT04424836 — intervention group
Intervention type: DEVICE
Intervention: high flow nasal cannula device
Description: device is supplying oxygen with heated and humidified air in a high flow rate
Study NCT01071993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Study NCT01563640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: permethrin insecticide
Description: commercial permethrin insecticide impregnation of clothing before transmission season
Study NCT01563640 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: washing
Description: normal washing of school uniforms, without permethrin insecticide impregnation
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmorubicin
Description: The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT03892330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirarubicin
Description: The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study NCT01426399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444
Description: LC15-0444 50mg qd (8 days once daily)
Study NCT01426399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg bid (8 days twice daily)
Study NCT01071993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Study NCT01426399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444+Metformin
Description: LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
Study NCT03172520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APS electrode
Description: The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.